Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compar...
Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative mitral regurgitation (MR) is a valvular heart disease often associated with the development...
Alternative Titles
Full title
Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b6a5d6bf79f2427abf2814b71fc27b1f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b6a5d6bf79f2427abf2814b71fc27b1f
Other Identifiers
ISSN
2055-5822
E-ISSN
2055-5822
DOI
10.1002/ehf2.14577
